Annals of Internal Medicine, tip sheet, December 3, 2002

December 02, 2002

Annals of Internal Medicine is published by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), an organization of more than 115,000 internal medicine physicians and medical students. The following highlights are not intended to substitute for articles as sources of information. For an embargoed fax of an article, call 1-800-523-1546, ext. 2656, or 215-351-2656.
* * *

Hospitalists Reduce Costs, Length of Hospital Stay and Short-Term Mortality

Two studies found lower costs, shorter hospital stays, and fewer deaths following hospitalization for patients under the care of hospitalists compared to those under the care of physicians who did not specialize in hospital care (Articles, p. 859 and p. 866). The benefits of hospitalists became evident only in the second year of both studies, indicating that hospitalist experience is important. An editorial says that these studies provide the best current evidence about hospitalist outcomes but do not show how hospitalists achieved favorable outcomes and do not prove that optimum hospital care requires hospitalists (Editorial, p. 930).
* * *

USPSTF Does Not Recommend For or Against Screening for Prostate Cancer

The United States Preventive Services Task Force (USPSTF), after reviewing published research on the benefits and harms of screening for prostate cancer, concluded that the evidence is insufficient to recommend for or against routine screening for prostate cancer using either digital rectal examination or prostate-specific antigen (PSA) tests (Clinical Guidelines, p. 915 and p. 917). The Task Force found good evidence that PSA screening detects early-stage prostate cancer but inconclusive evidence that early detection improves health outcomes or saves lives.
* * *

Study Examines Bone Density When Estrogen and Alendronate are Stopped

Researchers followed 244 postmenopausal women with low bone mass who took various combinations of bone-loss prevention drugs for two years, then stopped (Article, p. 875). At the end of three years, women who switched from alendronate or a combination of alendronate and estrogen to a placebo, or dummy pill, maintained bone density. Women who switched from estrogen alone to a placebo lost bone mass at greater rates than women who had never been on a drug to prevent bone loss. Women who continued taking the combination of alendronate and estrogen had spinal bone mineral density 11.2 percent higher than those in the three-year placebo group. All women in the study had had hysterectomies.
-end-


American College of Physicians

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.